The Molecular Pathology Shared Resource (MPSR) represents amalgamation of three existing cores (Cytogenetics, DNA Sequencing, and Pre-analytical Evaluation and Molecular Testing) into a thematically related and operationally coordinated unit. This consolidation creates a seamlessly integrated Shared Resource that mirrors an established CLIA-certified clinical service unit in the Department of Pathology. MPSR will facilitate the development and validation of clinical assays for diagnosis, prognostication, and, most importantly, prediction of response to molecular therapeutic agents for UCCC members. The newly organized Cytogenetics, DNA Sequencing, and Pathology Cores all have a long history within the UCCC. The Cytogenetics Core was started in 1988 and, since 1996, has been under the direction of Dr. Varella-Garcia. The Core began by providing UCCC members access to classical cytogenetic technology and has evolved over the years, in response to the scientific progress in the field, to provide members access to advanced technologies in both classical and molecular cytogenetics. The DNA Sequencing &Analysis Core has enjoyed a similar history, reputation and success. Dr. Korch has been with the (Dore since 1996, first as the manager, and more recently as the Director. The DNA Service is now the major in-state provider of DNA sequencing services to researchers in Colorado, performing basic, translational, and clinical cancer research, including CLIA-certified DNA sequencing services. The Pathology Core was established by Dr. Franklin's predecessor, Dr Gary Miller, in 1986 as one of the founding cores of the UCCC. Over the past 24 years, the core has provided tissue banking and histological services in support of UCCC research activities. Five years ago, lasercapture microdissection services were added to the resource. In 2008, the institution was awarded a clinical and translational sciences award (Colorado Clinical and Translational Sciences Initiative, or CCTSI), under which coordinated biobanking became a priority. Cancer Center leadership used this opportunity to leverage institutional and CCTSI support by consolidating tissue repository services previously under the Pathology Service Core, under the new leadership of Dr. Scott Lucia. This created a new UCCC Tissue Biobanking and Processing Shared Resource (TBP) Shared Resource.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA046934-25S2
Application #
8710576
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2013-02-01
Budget End
2014-01-31
Support Year
25
Fiscal Year
2013
Total Cost
$961
Indirect Cost
$339
Name
University of Colorado Denver
Department
Type
DUNS #
041096314
City
Aurora
State
CO
Country
United States
Zip Code
80045
Witt, Davis A; Donson, Andrew M; Amani, Vladimir et al. (2018) Specific expression of PD-L1 in RELA-fusion supratentorial ependymoma: Implications for PD-1-targeted therapy. Pediatr Blood Cancer 65:e26960
McCoach, Caroline E; Le, Anh T; Gowan, Katherine et al. (2018) Resistance Mechanisms to Targeted Therapies in ROS1+ and ALK+ Non-small Cell Lung Cancer. Clin Cancer Res 24:3334-3347
Abraham, Christopher G; Ludwig, Michael P; Andrysik, Zdenek et al. (2018) ?Np63? Suppresses TGFB2 Expression and RHOA Activity to Drive Cell Proliferation in Squamous Cell Carcinomas. Cell Rep 24:3224-3236
Sanchez, Gilson J; Richmond, Phillip A; Bunker, Eric N et al. (2018) Genome-wide dose-dependent inhibition of histone deacetylases studies reveal their roles in enhancer remodeling and suppression of oncogenic super-enhancers. Nucleic Acids Res 46:1756-1776
Noonan, Sinead A; Patil, Tejas; Gao, Dexiang et al. (2018) Baseline and On-Treatment Characteristics of Serum Tumor Markers in Stage IV Oncogene-Addicted Adenocarcinoma of the Lung. J Thorac Oncol 13:134-138
Guarnieri, A L; Towers, C G; Drasin, D J et al. (2018) The miR-106b-25 cluster mediates breast tumor initiation through activation of NOTCH1 via direct repression of NEDD4L. Oncogene 37:3879-3893
Davies, Kurtis D; Le, Anh T; Sheren, Jamie et al. (2018) Comparison of Molecular Testing Modalities for Detection of ROS1 Rearrangements in a Cohort of Positive Patient Samples. J Thorac Oncol 13:1474-1482
Lyu, Hui; Wang, Shuiliang; Huang, Jingcao et al. (2018) Survivin-targeting miR-542-3p overcomes HER3 signaling-induced chemoresistance and enhances the antitumor activity of paclitaxel against HER2-overexpressing breast cancer. Cancer Lett 420:97-108
Lee-Sherick, Alisa B; Jacobsen, Kristen M; Henry, Curtis J et al. (2018) MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. JCI Insight 3:
Drilon, Alexander; Laetsch, Theodore W; Kummar, Shivaani et al. (2018) Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. N Engl J Med 378:731-739

Showing the most recent 10 out of 1634 publications